Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Erlin Marte

Endocrinology, Diabetes & Metabolism Buffalo, NY Doctor of Osteopathy

NPI 1316204290 CMS profile 1383521

85 High St, Buffalo, NY 14203

Open in the dashboard

General payments

$570,348

833 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Erlin Marte of Buffalo, NY is reported in the CMS Open Payments database as having received $570,348 across 833 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $161,418 175
2024 General $112,728 175
2023 General $100,159 186
2022 General $84,667 123
2021 General $48,027 52
2020 General $50,495 86
2019 General $12,854 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Erlin Marte
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Erlin Marte were reported at $161,418. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Erlin Marte Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $12,854 $494 $123–$2,253 $163
2020 $50,495 $335 $85–$1,841 $114
2021 $48,027 $398 $88–$1,981 $132
2022 $84,667 $364 $88–$1,568 $149
2023 $100,159 $420 $113–$1,614 $160
2024 $112,728 $440 $121–$1,646 $164
2025 $161,418 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $334,281 574 payments
  2. Novo Nordisk Inc $120,145 136 payments
  3. Sanofi-Aventis U.S. LLC $88,461 76 payments
  4. Genzyme Corporation $18,722 3 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $7,328 20 payments
  6. Corcept Therapeutics $331 3 payments
  7. Horizon Therapeutics plc $243 2 payments
  8. Mannkind Corporation $203 4 payments
  9. Amgen Inc. $159 2 payments
  10. Janssen Scientific Affairs, LLC $150 2 payments
  11. Other $324 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $487,402 345 payments
  2. Travel and Lodging $51,209 195 payments
  3. Food and Beverage $15,637 267 payments
  4. Consulting Fee $15,426 3 payments
  5. Education $614 22 payments
  6. Gift $59 1 payment
Products named General payments · program years 2019–2025
  1. MOUNJARO $281,440 475 payments
  2. TZIELD $106,028 75 payments
  3. Saxenda $88,156 89 payments
  4. Wegovy $31,484 27 payments
  5. JARDIANCE Diabetes $17,843 24 payments
  6. JARDIANCE Diabetes $7,328 20 payments
  7. LYUMJEV $5,218 9 payments
  8. TOUJEO $1,101 2 payments
  9. Victoza $420 13 payments
  10. Korlym $331 3 payments
  11. Other $1,297 42 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

833 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record